Table 1

Patient characteristics

2007–2016
(n=75)
2017–2021
(n=204)
P value
Age, years, mean±SD63.2±12.1460.80±14.900.216
FIGO stage at diagnosis, n (%)0.435
 III57 (76.0%)144 (70.6%)
 IV18 (24.0%)58 (28.4%)
 Missing0 (0.0%)2 (1.0%)
Neoadjuvant chemotherapy, n (%)<0.001*
 Yes67 (89.3%)111 (54.4%)
 No8 (10.7%)93 (45.6%)
 Missing
Residual disease, n (%)0.023*
 Yes14 (18.7%)18 (8.8%)
 No61 (81.3%)185 (90.7%)
 Missing0 (0.0%)1 (0.5%)
BRCA mutation, n (%)0.842
 No mutation24 (32.0%)53 (26.0%)
 BRCA 1 or BRCA 2 mutation8 (10.7%)16 (7.8%)
 Missing43 (57.3%)135 (66.2%)
Initial CA125, median (P25–P75)<0.001*
 Initial CA125 (IU/L)1283 (257–2424)336 (96–861)
Histological type, n (%)<0001*
 Serous/serous papillary50 (74.6%)167 (85.6%)
 Mucinous0 (0.0%)5 (2.6%)
 Endometrioid6 (8.9%)5 (2.6%)
 Clear cells1 (1.5%)1 (0.5%)
 Undifferentiated10 (14.9%)2 (1.0%)
 Other0 (0.0%)15 (7.7%)
 Missing8 (10.7%)9 (4.4%)
Grade, n (%)0.571
 Low grade (I–II)7 (9.3%)24 (11.8%)
 High grade (III)60 (80.0%)159 (77.9%)
 Missing8 (10.7%)21 (10.3%)
Ascites, n (%)0.267
 Yes49 (65.3%)122 (59.8%)
 No8 (10.7%)32 (15.7%)
 Missing18 (24.0%)50 (24.5%)
Ascites volume, n (%)<0.001*
 No ascite8 (10.7%)32 (15.7%)
 0–500 mL14 (18.7%)72 (35.3%)
 500 mL–1 L3 (4.0%)13 (6.4%)
 1–3 L18 (24.0%)13 (6.4%)
 >3 L14 (18.7%)24 (11.8%)
 Missing18 (24.0%)50 (24.5%)
Maintenance therapy, n (%)0.011*
 Yes7 (9.3%)47 (23.0%)
 No67 (89.3%)157 (77.0%)
 Missing1 (1.3%)0 (0.0%)
Maintenance therapy drug (patients with maintenance therapy: n=54)<0.001*
 PARPi0 (0.0%)43 (91.5%)
 Bevacizumab7 (100.0%)4 (8.5%)
  • *Statistically significant.

  • BRCA, breast cancer gene; CA125, cancer antigen 125; FIGO, International Federation of Gynecology and Obstetrics; PARPi, poly(ADP-ribose) polymerase inhibitor.